[Featured Stock] LaMeditech Strengthens as Laser Blood Collection Device Officially Enters US Market

Rameditech is showing strong performance. The expectation that the laser blood collection device 'HandyRay Series' will officially enter the U.S. market seems to have had an impact.

As of 10:05 AM on the 25th, Rameditech was trading at 11,660 KRW, up 1,410 KRW (13.76%) compared to the previous trading day.

On the 22nd of this month, Rameditech announced that the CEO of A2A Logistics (a medical device and pharmaceutical specialized distribution company and a prime vendor for the U.S. federal government) and a sourcing expert from Kaiser Permanente (a comprehensive healthcare service provider group) visited Rameditech’s headquarters. They tested the product line and discussed entry into the U.S. market, initiating steps toward global market expansion.

Founded in 2010, A2A Logistics is a distribution company supplying medical, surgical, and laboratory equipment to U.S. government and private institutions, and is a pharmaceutical distributor certified by the National Community Pharmacists Association. Kaiser Permanente, established in 1945, operates 40 hospitals and 616 medical offices across multiple U.S. states including California and Washington, providing comprehensive healthcare services.

Choi Jong-seok, CEO of Rameditech, said, "We are pleased that the visit by A2A Logistics and Kaiser Permanente to our headquarters has enabled us to actively pursue entry into the U.S. public procurement and healthcare markets." He added, "Going forward, Rameditech will continue to strive for world-class technology in laser technology and medical devices, and we will do our best to develop into a global medical device company representing Korea."